Gut microbiota dysfunction as reliable non-invasive early diagnostic biomarkers in the pathophysiology of Parkinson's disease: A critical review

Journal of Neurogastroenterology and Motility

Volumn 24, Issue 1, 2018, Pages 30-42

  Nair, Arun T ^a   Ramachandran, Vadivelan ^a   Joghee, Nanjan M ^b   Antony, Shanish ^c   Ramalingam, Gopalakrishnan ^a  

^a JSS ACADEMY OF HIGHER EDUCATION AND RESEARCH   (India)

^b JSS COLLEGE OF PHARMACY   (India)

^c GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

Biomarkers; Constipation; Gastrointestinal microbiome; Humans alpha synuclein; Parkinson disease

Indexed keywords

ACETIC ACID; ALPHA SYNUCLEIN; AMANTADINE; BIOLOGICAL MARKER; BUTYRIC ACID; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MONOAMINE OXIDASE B INHIBITOR; NEUROTROPHIC FACTOR; OCCLUDIN; PROPIONIC ACID; SEROTONIN;

ACTINOBACTERIA; ARCHAEON; BACTERIAL OVERGROWTH; BACTEROIDETES; BIFIDOBACTERIUM; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CHRONIC INFLAMMATION; CLINICAL FEATURE; CONSTIPATION; DIGESTIVE SYSTEM INFLAMMATION; DOPAMINE METABOLISM; DYSBIOSIS; DYSPHAGIA; EARLY DIAGNOSIS; ECHOGRAPHY; ENTEROBACTERIACEAE; ENTEROCOCCUS; FAECALIBACTERIUM PRAUSNITZII; FIRMICUTES; GASTROINTESTINAL TRACT; HUMAN; HYPERSALIVATION; IMMUNOCOMPETENT CELL; INTESTINE FLORA; INTESTINE INNERVATION; INTESTINE MUCOSA PERMEABILITY; LACTOBACILLUS; MALNUTRITION; METHANOBREVIBACTER SMITHII; MOUTH DISEASE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROTEOBACTERIA; PROTON NUCLEAR MAGNETIC RESONANCE; RELIABILITY; REVIEW; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; STOMACH FUNCTION DISORDER; TOOTH DISEASE; VERRUCOMICROBIA;

EID: 85039938075     PISSN: 20930879     EISSN: 20930887     Source Type: Journal    
DOI: 10.5056/jnm17105     Document Type: Review

References (148)

1. Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm 2017;124:901-905
2. Statistics on Parkinson's disease. Parkinson Association of the Carolinas. Available from URL: http://www.parkinsonassociation.org/ (accessed 11 December, 2017)
3. Schapira AH. Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol 2013;26:395-400
4. Kalia LV, Lang AE. Parkinson's disease. Lancet 2015;386:896-912
5. Garcia-Ruiz PJ, Chaudhuri KR, Martinez-Martin P. Non-motor symptoms of parkinson's disease a review from the past. J Neurol Sci 2014;338:30-33
6. Dietert J, Dietert R. The sum of our parts. Scientist 2015;29:44-49
7. Fond G, Boukouaci W, Chevalier G, et al. The 'psychomicrobiotic': targeting microbiota in major psychiatric disorders: a systematic review. Pathol Biol (Paris) 2015;63:35-42
8. Forsythe P, Sudo N, Dinan T, Taylor VH, Bienenstock J. Mood and gut feelings. Brain Behav Immun 2010;24:9-16
9. Shakir R. Neurodegenerative noncommunicable diseases (Neurology NCDs). Where are we now? J Neurol Sci 2015;356:1-2
10. Silberberg D, Anand NP, Michels K, Kalaria RN. Brain and other nervous system disorders across the lifespan-global challenges and opportunities. Nature 2015;527:S151-S154
11. Wolters ECh, Braak H. Parkinson's disease: premotor clinico-pathological correlations. J Neural Transm Suppl 2006;70:309-319
12. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 2007;30:244-250
13. Doudet D, Ruth T. Imaging the brain in Parkinson's disease: BC Med 2001;3:148-152
14. Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL. Limitations of current Parkinson's disease therapy. Ann Neuro 2003;53:S3-12; discussion S12-S15
15. Murman DL. Early treatment of Parkinson's disease: opportunities for managed care. Am J Manag Care 2012;18:S183-S188
16. Lancet Neurology. Building on 50 years of levodopa therapy. Lancet Neurol 2016;15:1
17. Picillo M, Moccia M, Spina E, Barone P, Pellecchia MT. Biomarkers of Parkinson's disease: recent insights, current challenges, and future prospects. J Parkinsonism Restless Legs Syndr 2016;6:1-13
18. DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science 2003;302:830-834
19. Scherzer C. Interview-Searching for biomarkers in Parkinson's disease. Biomark Med 2009;3:1134
20. O'Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ. Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinico pathological study. Mov Disord 2008;23:101-106
21. Barber TR, Klein JC, Mackay CE, Hu MTM. Neuroimaging in pre-motor Parkinson's disease. Neuroimage Clin 2017;15:215-227
22. Cryan JF, O'Mahony SM. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil 2011;23:187-192
23. De Palma G, Collins SM, Bercik P, Verdu EF. The microbiota-gut-brain axis in gastrointestinal disorders: stressed bugs, stressed brain or both? J Physiol 2014;592:2989-2997
24. Mayer EA, Tillisch K, Bradesi S. Review article: modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease. Aliment Pharmacol Ther 2006;24:919-933
25. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012;13:701-712
26. Aziz Q, Doré J, Emmanuel A, Guarner F, Quigley EM. Gut microbiota and gastrointestinal health: current concepts and future directions. Neurogastroenterol Motil 2013;25:4-15
27. Bonaz BL, Bernstein CN. Brain-gut interactions in inflammatory bowel disease. Gastroenterology 2013;144:36-49
28. Davari S, Talaei SA, Alaei H, Salami M. Probiotics treatment improves diabetes-induced impairment of synaptic activity and cognitive function: behavioral and electrophysiological proofs for microbiome-gut-brain axis. Neuroscience 2013;240:287-296
29. Grenham S, Clarke G, Cryan JF, Dinan TG. Brain-gut-microbe communication in health and disease. Front Physiol 2011;2:94
30. Mayer EA. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci 2011;12:453-466
31. Quigley EM, Monsour HP. The gut microbiota and nonalcoholic fatty liver disease. Semin Liver Dis 2015;35:262-269
32. O'Mahony SM, Hyland NP, Dinan TG, Cryan JF. Maternal separation as a model of brain-gut axis dysfunction. Psychopharmacology (Berl) 2011;214:71-88
33. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 2009;6:306-314
34. Thakur AK, Shakya A, Husain GM, Emerald M, Kumar V. Gut-microbiota and mental health: current and future perspectives. J Pharmacol Clin Toxicol 2014;2:1016
35. Blekhman R, Goodrich JK, Huang K, et al. Host genetic variation impacts microbiome composition across human body sites. Genome Biol 2015;16:191
36. Bäckhed F, Roswall J, Peng Y, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 2015;17:690-703
37. Debnath M, Venkatasubramanian G, Berk M. Fetal programming of schizophrenia: select mechanisms. Neurosci Biobehav Rev 2015;49:90-104
38. Dominguez-Bello MG, Blaser MJ. Asthma: undoing millions of years of coevolution in early life? Sci Transl Med 2015;7:307fs39
39. Van Opstal EJ, Bordenstein SR. Rethinking heritability of the microbiome. Science 2015;349:1172-1173
40. Dominguez-Bello MG, De Jesus-Laboy KM, Shen N, et al. Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer. Nat Med 2016;22:250-253
41. Gomez de Agüero M, Ganal-Vonarburg SC, Fuhrer T, et al. The maternal microbiota drives early postnatal innate immune development. Science 2016;351:1296-1302
42. Al-Asmakh M, Hedin L. Microbiota and the control of blood-tissue barriers. Tissue Barriers 2015;3:e1039691
43. McKenney PT, Pamer EG. From hype to hope: the gut microbiota in enteric infectious disease. Cell 2015;163:1326-1332
44. Scharschmidt TC, Vasquez KS, Truong HA, et al. A wave of regulatory T cells into neonatal skin mediates tolerance to commensal microbes. Immunity 2015;43:1011-1021
45. Wang Z, Roberts AB, Buffa JA, et al. Non-lethal inhibition of gut microbial tri methylamine production for the treatment of atherosclerosis. Cell 2015;163:1585-1595
46. Yang I, Corwin EJ, Brennan PA, Jordan S, Murphy JR, Dunlop A. The infant microbiome: Implications for infant health and neurocognitive development. Nurs Res 2016;65:76-88
47. Hinde K, Lewis ZT. Mother's littlest helpers. Science 2015;348:1427-1428
48. Meadow JF, Altrichter AE, Bateman AC, et al. Humans differ in their personal microbial cloud. Peer J 2015;3:e1258
49. Zeevi D, Korem T, Zmora N, et al. Personalized nutrition by prediction of glycemic responses. Cell 2015;163:1079-1094
50. Zuker CS. Food for the brain. Cell 2015;161:9-11
51. Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 2012;10:735-742
52. Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. J Clin Invest 2015;125:926-938
53. Sampson TR, Mazmanian SK. Control of brain development, function, and behavior by the microbiome. Cell Host Microbe 2015;17:565-576
54. Friedland RP. Mechanisms of molecular mimicry involving the microbiota in neurodegeneration. J Alzheimers Dis 2015;45:349-362
55. Del Tredici K, Rüb U, De Vos RA, Bohl JR, Braak H. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002;61:413-426
56. Ueki A, Otsuka M. Life style risks of Parkinson's disease: association between decreased water intake and constipation. J Neurol 2004;251(suppl 7):vII18-vII23
57. Cersosimo MG, Benarroch EE. Pathological correlates of gastrointestinal dysfunction in Parkinson's disease. Neurobiol Dis 2012;46:559-564
58. Forsyth CB, Shannon KM, Kordower JH, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early parkinson's disease. PLoS One 2011;6:e28032
59. Devos D, Lebouvier T, Lardeux B, et al. Colonic inflammation in parkinson's disease. Neurobiol Dis 2013;50:42-48
60. Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol 2008;15(suppl 1):14-20
61. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in meissner's and auerbach's plexuses in cases staged for parkinson's disease related brain pathology. Neurosci Lett 2006;396:67-72
62. Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord 2012;27:716-719
63. Kieburtz K, Wunderle KB. Parkinson's disease: evidence for environmental risk factors. Mov Disord: 2013;28:8-13
64. Savica R, Carlin JM, Grossardt BR, et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 2009;73:1752-1758
65. çamci G, Oguz S. Association between Parkinson's disease and helicobacter pylori. J Clin Neurol 2016;12:47-50
66. Fasano A, Bove F, Gabrielli M, et al. The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2013;28:1241-1249
67. Tan AH, Mahadeva S, Thalha AM, et al. Small intestinal bacterial overgrowth in Parkinson's disease. Parkinsonism Relat Disord 2014;20:535-540
68. Keshavarzian A, Green SJ, Engen PA, et al. Colonic bacterial composition in Parkinson's disease. Mov Disord 2015;1351-1360
69. Eisenhofer G, Aneman A, Friberg P, et al. Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab 1997;82:3864-3871
70. Wall R, Cryan JF, Ross RP, Fitzgerald GF, Dinan TG, Stanton C. Bacterial neuroactive compounds produced by psychobiotics. Adv Exp Med Biol 2014;817:221-239
71. Brenner SR. Blue-green algae or cyanobacteria in the intestinal micro-flora may produce neurotoxins such as Beta-N-Methylamino-L-Alanine (BMAA) which may be related to development of Amyotrophic lateral sclerosis, Alzheimer's disease and Parkinson-dementia-complex in humans and equine motor neuron disease in horses. Med Hypotheses 2013;80:103
72. Edelblum KL, Turner JR. The tight junction in inflammatory disease: communication breakdown. Curr Opin Pharmacol 2009;9:715-720
73. Scher JU, UbedaC, Artacho A, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol 2015;67:128-139
74. Rana SV. Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease. Dig Dis Sci 2013;58:2594-2598
75. Kelly LP, Carvey PM, Keshavarzian A, et al. Progression of intestinal permeability changes and alphasynuclein expression in a mouse model of Parkinson's disease. Mov Disord 2014;29:999-1009
76. Klein C, Westenberger A. Genetics of Parkinson's disease. Cold Spring Harb Perspect Med 2012;2:a008888
77. Fraher MH, O'Toole PW, Quigley EM. Techniques used to characterize the gut microbiota: a guide for the clinician. Nat Rev Gastroenterol Hepatol 2012;9:312-322
78. Dutkiewicz J, Szlufik S, Nieciecki M, et al. Small intestine dysfunction in Parkinson's disease. J Neural Transm (Vienna) 2015;122:1659-1661
79. Sakakibara R, Odaka T, Uchiyama T, et al. Colonic transit time and rectoanal video manometry in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:268-272
80. Goldman JG, Postuma R. Premotor and non-motor features of Parkinson's disease. Curr Opin Neurol 2014;27:434-441
81. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001;57:456-462
82. Gao X, Chen H, Schwarzschild MA, Ascherio A. A prospective study of bowel movement frequency and risk of Parkinson's disease. Am J Epidemiol 2011;174:546-551
83. Chen H, Zhao EJ, Zhang W, et al. Meta-analyses on prevalence of selected Parkinson's non motor symptoms before and after diagnosis. Transl Neurodegener 2015;4:1
84. Adams-Carr KL, Bestwick JP, Shribman S, Lees A, Schrag A, Noyce AJ. Constipation preceding Parkinson's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2015;87:710-716
85. Postuma RB, Gagnon JF, Pelletier A, Montplaisir J. Prodromal autonomic symptoms and signs in parkinson's disease and dementia with lewy bodies. Mov Disord 2013;28:597-604
86. Gold A, Turkalp ZT, Munoz DG. Enteric alpha-synuclein expression is increased in Parkinson's disease but not Alzheimer's disease. Mov Disord 2013;28:237-240
87. Hilton D, Stephens M, Kirk L, et al. Accumulation of alpha-synuclein in the bowel of patients in the pre-clinical phase of Parkinson's disease. Acta Neuropathol 2014;127:235-241
88. Shannon KM, Keshavarzian A, Mutlu E, et al. Alpha-synuclein in colonic submucosa in early untreated parkinson's disease. Mov Disord 2012;27:709-715
89. Wang L, Fleming SM, Chesselet MF, Taché Y. Abnormal colonic motility in mice over expressing human wild-type alpha-synuclein. Neuroreport 2008;19:873-876
90. Hallett PJ, McLean JR, Kartunen A, Langston JW, IsacsonO. Alpha-synuclein over expressing transgenic mice shows internal organ pathology and autonomic deficits. Neurobiol Dis 2012;47:258-267
91. Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with lewy body disorders. Acta Neuropathol 2010;119:689-702
92. Lebouvier T, Neunlist M, Bruley des Varannes S, et al. Colonic biopsies to assess the neuropathology of parkinson's disease and its relationship with symptoms. PLoS One 2010;5:e12728
93. Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. Parkinson's disease: the presence of lewy bodies in auerbach's and meissner's plexuses. Acta Neuropathol 1988;76:217-221
94. Lebouvier T, Chaumette T, Damier P, et al. Pathological lesions in colonic biopsies during parkinson's disease. Gut 2008;57:1741-1743
95. Clairembault T, Leclair-Visonneau L, Coron E, et al. Structural alterations of the intestinal epithelial barrier in parkinson's disease. Acta Neuropathol Commun 2015;3:12
96. Shaikh M, Rajan K, Forsyth CB, Voigt RM, Keshavarzian A. Simultaneous gas-chromatographic urinary measurement of sugar probes to assess intestinal permeability: use of time course analysis to optimize its use to assess regional gut permeability. Clin Chim Acta 2015;442:24-32
97. Hasegawa S, Goto S, Tsuji H, et al. Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in parkinson's disease. PLoS One 2015;10:e0142164
98. Salat-Foix D, Tran K, Ranawaya R, Meddings J, Suchowersky O. Increased intestinal permeability and Parkinson disease patients: chicken or egg? Can J Neurol Sci 2012;39:185-188
99. Gabrielli M, Bonazzi P, Scarpellini E, et al. Prevalence of small intestinal bacterial overgrowth in parkinson's disease. Mov Disord 2011;26:889-892
100. Cassani E, Barichella M, Dancello R, et al. Increased urinary indoxyl sulfate (indican): new insights into gut dysbiosis in Parkinson's disease. Parkinsonism Relat Disord 2015;21:389-393
101. Scheperjans F, Aho V, Pereira PA, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord 2015;30:350-358
102. Soret R, Chevalier J, De Coppet P, et al. Short-chain fatty acids regulate the enteric neurons and control gastrointestinal motility in rats. Gastroenterology 2010;138:1772-1782
103. Unger MM, Spiegel J, Dillmann KU, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. Parkinsonism Relat Disord 2016;32:66-72
104. Mukherjee A, Biswas A, Das SK. Gut dysfunction in Parkinson's disease. World J Gastroenterol 2016;22:5742-5752
105. Förster C. Tight junctions and the modulation of barrier function in disease. Histochem Cell Biol 2008;130:55-70
106. Dobbs RJ, Charlett A, Dobbs SM, et al. Leukocyte-subset counts in idiopathic Parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial over growth. A surveillance study. Gut Pathog 2012;4:12
107. Charlett A, Dobbs RJ, Purkiss AG, et al. Cortisol is higher in Parkinsonism and associated with gait deficit. Acta Neurol Scand 1998;97:77-85
108. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW. Association of circulating TNF-alpha and IL-6 with ageing and Parkinsonism. Acta Neurol Scand 1999;100:34-41
109. Reale M, Iarlori C, Thomas A, et al. Peripheral cytokines profile in parkinson's disease. Brain Behav Immun 2009;23:55-63
110. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol 2008;167:90-95
111. Yano JM, Yu K, Donaldson GP, et al. Indigenous bacteria from the gut microbiota regulates host serotonin biosynthesis. Cell 2015;161:264-276
112. Hsu YT, Liao CC, Chang SN, et al. Increased risk of depression in patients with Parkinson disease: a nationwide cohort study. Am J Geriatr Psychiatry 2015;23:934-940
113. Tong Q, Zhang L, Yuan Y, et al. Reduced plasma serotonin and 5-hydroxyindoleacetic acid levels in Parkinson's disease are associated with nonmotor symptoms. Parkinsonism Relat Disord 2015;21:882-887
114. Maes M, Kubera M, Leunis JC. The gut-brain barrier in major depression: Intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett 2008;29:117-124
115. Schicho R, Shaykhutdinov R, Ngo J, et al. Quantitative metabolomic profiling of serum, plasma, and urine by H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals. J Proteome Res 2012;11:3344-3357
116. Van Berkel JJ, Dallinga JW, Möller GM, et al. A profile of volatile organic compounds in breath discriminates COPD patients from controls. Respir Med 2010;104:557-563
117. Szczesniak O, Hestad KA, Hanssen JF, Rudi K. Isovaleric acid in stool correlates with human depression. Nutr Neurosci 2016;19:279-283
118. Liepelt-Scarfone I, Gauss K Maetzler W, et al. Evaluation of progression markers in the premotor phase of Parkinson's disease: the progression markers in the premotor phase study. Neuroepidemiology 2013;41:174-182
119. Saeed U, Compagnone J, Aviv RI, et al. Imaging biomarkers in Parkinson's disease and Parkinsonian symptoms: current and emerging concepts. Transl Neurodegener 2017;6:8
120. Sharma S, Moon CS. Biomarkers in Parkinson's disease (recent update). Neurochem Int 2013;63:201-229
121. Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol 2008;7:1044-1055
122. Gaig C, Tolosa E. When does Parkinson's disease begin? Mov Disord 2009;24(suppl 2):S656-S664
123. Tuite PJ, Mangia S. Magnetic resonance imaging (MRI) in Parkinson's disease. J Alzheimers Dis Parkinsonism 2013;(suppl 1):001
124. Poewe W, Mahlknecht P. Combined assessment of midbrain hyperechogenicity, hyposmia and motor asymmetry improves diagnostic accuracy in early Parkinson's disease. Expert Rev Neurother 2012;12:911-914
125. Shao N, Yang J, Li J, Shang HF. Voxelwise meta-analysis of gray matter anomalies in progressive supranuclear palsy and parkinson's disease using anatomic likelihood estimation. Front Hum Neurosci 2014;8:63
126. Berg D, Lang AE, Postuma RB, et al. Change the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol 2013;12:514-524
127. Berg D, Marek K, Ross GW, Poewe W. Defining at-risk populations for Parkinson 's disease: lessons from ongoing studies. Mov Disord 2012;27:656-665
128. Lerche S, Hobert M, Brochmann K, et al. Mild parkinsonian signs in the elderly-Is there an association with PD? Crossectional findings in 992 individuals. PLoS One 2014;9:e92878
129. Noyce AJ, Bestwick JP, Silveira-Moriyam L et al. PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results. J Neurol Neurosur Psychiatry 2014;85:31-37
130. Berg D, Postuma RB, Bloem B, et al. Time to redefine PD? Introductory statement of the MDS task force on the definition of Parkinson's disease. Mov Disord 2014;29:454-462
131. Bhidayasiri R, Reichmann H. Different diagnostic criteria for Parkinson disease: what are the pitfalls? J Neural Transm (Vienna) 2013;120:619-625
132. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009; 373:2055-2066
133. Deutch AY. Parkinson's disease redefined. Lancet Neurol 2013;12:422-423
134. Wang N, Gibbons CH, Lafo J, Freeman R. a-synuclein in cutaneous autonomic nerves. Neurol 2013;81:1604-1610
135. del Campo M, Mollenhauer B, Bertolotto A. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med 2012;6:419-430
136. Van Dijk KD, Teunissen CE, Drukarch B, et al. Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. Neurobiol Dis 2010;39:229-241
137. Mielke MM, Maetzler W. A 'bird's eye' view on the current status and potential benefits of blood biomarkers for Parkinson's disease. Biomarkers Med 2014;8:225-227
138. Saracchi E, Fermi S, Brighina L. Emerging candidate biomarkers for Parkinson's disease: a review. Aging Dis 2013;5:27-34
139. Rappaport SM. Biomarkers intersect with the exposome. Biomarkers 2012;17:483-489
140. Bogdanov M, Matson WR, Wang L, et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008;131(pt 2):389-396
141. Rappaport SM, Barupal DK, Wishart D, Vineis P, Scalbert A. The blood exposome and its role in discovering causes of disease. Environ Health Perspect 2014;122:769-774
142. Ahmed SS, Santosh W, Kumar S, Christlet HTT. Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J Biomed Sci 2009;16:63
143. Burgos K, Malenica I, Metpally R, et al. Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology. PLoS One 2014;9:e94839
144. DeKosky ST, Gandy S. Environmental exposures and the risk for Alzheimer disease: can we identify the smoking guns? JAMA Neurol 2014;71:273-275
145. Mulak A, Bonaz B. Brain-gut-microbiota axis in Parkinson's disease. World J Gastroenterol 2015;21:10609-10620
146. Principi N, Esposito S. Gut microbiota and central nervous system development. J Infect 2016;73:536-546
147. Yarandi SS, Peterson DA, Treisman GJ, Moran TH, Pasricha PJ. Modulatory effects of gut microbiota on the central nervous system: how gut could play a role in neuropsychiatric health and diseases. J Neurogastroenterol Motil 2016;22:201-212
148. Houser MC, Tansey MG. The gut-brain axis: is intestinal inflammation a silent driver of Parkinson's disease pathogenesis? NPJ Parkinson's Dis 2017;3:3